Navigation Links
Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis

tients who reported complete resolution of one cardinal symptom there was an average improvement in endoscopy scores of 12%. In patients who reported resolution of both cardinal symptoms there was an average improvement in endoscopy scores of 23%."

The clinical trial has reached approximately 80% enrollment and the Company believes it will finish enrollment of the 300 patients required for randomization during the summer. Unblinded top-line results for all patients are expected to be available before the end of the year.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company" or "Accentia") is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune, to treat nume
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/17/2013)... The power of plants to cure and ... mankind depends on the plant kingdom, is the subject ... Wild Medicine: Healing Plants Around the World, ... May 18 through September 8, 2013. ... many attractions include a re-creation of the Western world,s ...
(Date:5/17/2013)... 2013 Medical devices are any medical items ... In light of their different mechanisms, actions and regulatory ... complicated than drug trails due to their unique clinical ... of evaluating both safety and efficacy (which is left ... the same as the SFDA) evaluate MDs for both ...
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. ... of protective clothing for industry, healthcare and to first ... release its financial results for the fiscal 2013 fourth ... May 21, 2013 at stock market close and will ... 4:30 p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ...
Breaking Medicine Technology:Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2Statistical Challenges in Medical Device Trail Evaluation 2Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2
... , BOZEMAN, Mont., Sept 8 ... its third human clinical trial of its norovirus vaccine. ... with LigoCyte,s investigational, nasally-delivered, dry powder vaccine in healthy adults. ... of norovirus infection by including a live virus challenge of ...
... , MORGANTON, W.Va., Sept. 4 People with chronic ... and depression than people treated conventionally for back pain, a West ... , , The three-year, $400,000 study, published in ... pain and improved function in the group that did yoga postures ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 2LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 3Yoga Benefits Back-Pain Patients 2
(Date:5/18/2013)... The “World Healthcare IT Market: Trends ... major market drivers, restraints, and opportunities in North America, ... , 89 market data tables ... "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... , The global healthcare IT market is expected to ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... Miami, FL (PRWEB) May 18, 2013 ... and Nioxin. Pattern hair loss is not a result ... cap. According to Men’s Fitness Magazine, 70% of men ... Bosley Professional Strength is renowned for hair transplant ... that fights male pattern baldness known as Bosley Professional ...
(Date:5/18/2013)... Washington DC (PRWEB) May 18, 2013 Family ... Best" designation for excellence by Follow Media Consulting, Inc. in ... award signifies the continued commitment and dedication of the areas ... lifestyle. , No one knows parenting better than Brenda Hyde, ... goal is to help parents know about the vast resources ...
(Date:5/18/2013)... 2013 As metal-on-metal hip implant ... country, Bernstein Liebhard LLP notes that a new study ... tissue damage before they experience any pain from a ... Daily will appear in the Journal of Bone & ... screens of their hips. The researchers found tissue ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... of DuPont Participation for Leading International ... Companies, SEOUL, ... Health at Work, DuPont (NYSE: DD ) today,announced its participation as the ... be held here June 29 to July 2., Held every three years, ...
... Accuracy improvements will help prepare the organization to maximize ... reimbursements as NY state converts to ... Systems, Inc.,announces that Heritage Ministries Management Company, Inc, with,headquarters ... their enterprise, which includes three skilled nursing,facilities with more ...
... N.J., April 28 Karrie Fairbrother, BSN,RN, CDE, ... Nurses,Association (DNA), a national professional nursing organization dedicated,to ... new role as president, Fairbrother, a nurse educator ... to increase the visibility,of the DNA as an ...
... the April issue of the Journal of Alzheimers Disease presents ... Alzheimer,s disease. It demonstrates that an abnormal form of ... produced in very simple cell models in an unambiguous way. ... chemical compound, found in nature, which is highly effective to ...
... Milestone,Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in,advanced injection ... STA(TM) System at the upcoming,California Dental Association (CDA) 2008 Spring Scientific Session., ... WHERE: Booth #1641 ... 800 West Katella Avenue ...
... NEW YORK, April 28 Crystal Research Associates, ... Informational Overview(R),(EIO(R)) on Advaxis, Inc. (OTC Bulletin Board: ... http://www.crystalra.com ., Advaxis, Inc. ("Advaxis" or ... to safely create vaccines that,stimulate multiple immune responses ...
Cached Medicine News:Health News:DuPont Announces Sponsorship of XVIII World Congress on Safety and Health at Work 2Health News:DuPont Announces Sponsorship of XVIII World Congress on Safety and Health at Work 3Health News:The Heritage Group Selects AccuNurse(R) to Improve Efficiency and Deliver Proactive Care 2Health News:The Heritage Group Selects AccuNurse(R) to Improve Efficiency and Deliver Proactive Care 3Health News:New Dermatology Nurses' Association President Fairbrother to Work to Increase Visibility of Organization, Profession 2Health News:Milestone Scientific to Exhibit at the California Dental Association (CDA) Spring Scientific Session 2Health News:Milestone Scientific to Exhibit at the California Dental Association (CDA) Spring Scientific Session 3Health News:Milestone Scientific to Exhibit at the California Dental Association (CDA) Spring Scientific Session 4Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc. 2Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc. 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: